By: Tatiana Prowell, M.D., Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology Oncology Products, at FDA’s Center for Drug Evaluation and Research and Richard Pazdur, M.D., Director of the Office of Hematology and Oncology Products at FDA’s Center for Drug Evaluation and Research
Last month, researchers at an international oncology conference in Spain reported that pertuzumab, which was FDA-approved for treatment of HER2+ metastatic breast cancer in June 2012, improved survival by an average of nearly 16 months when added to standard treatment. This was yet another piece of good news, and one of unprecedented magnitude, for patients living with what was once the most dreaded type of breast cancer.
Tatiana Prowell, M.D., Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology Oncology Products, and Richard Pazdur, M.D., Director of the Office of Hematology and Oncology Products, both of FDA’s Center for Drug Evaluation and Research
In the past, the next step would have been to wait for years while large clinical trials were conducted to determine if the drug also worked for earlier stages of breast cancer. This is beginning to change.
Read More: Getting Potentially Life-Saving Drugs to High-Risk Breast Cancer Patients Faster
Tatiana Prowell, M.D., Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology Oncology Products, and Richard Pazdur, M.D., Director of the Office of Hematology and Oncology Products, both of FDA’s Center for Drug Evaluation and Research
In the past, the next step would have been to wait for years while large clinical trials were conducted to determine if the drug also worked for earlier stages of breast cancer. This is beginning to change.
Read More: Getting Potentially Life-Saving Drugs to High-Risk Breast Cancer Patients Faster
No hay comentarios:
Publicar un comentario